Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1406 · 1 trial · 1 indication
Blood samples will be collected at pre-specified timepoints to determine the AUC0-4w of MK-1406.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Solicited injection-site reactions include tenderness, pain, redness/erythema, and swelling. Participants will record injection site reactions using a paper diary. The number of participants with solicited injection-site reactions will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-1406 3-Injections | EXPERIMENTAL | Participants receive 3 subcutaneous (SQ) injections of MK-1406 on Day 1. |
| MK-1406 2-Injections | EXPERIMENTAL | Participants receive 2 SQ injections of MK-1406 on Day 1. |
| Name | Type | Description |
|---|---|---|
| MK-1406 | DRUG | Subcutaneous administration |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant en...
MK-1406 is an investigational small molecule drug being developed by Merck & Company, Inc. It is currently in Phase 1 clinical development. The specific disease or condition it is intended to treat has not been disclosed, and the program sits outside the main therapeutic areas typically reported for Merck's pipeline.
MK-1406 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program for this asset.
MK-1406 is in Phase 1 clinical development. It is an investigational drug and is not approved for any use. The program currently has one trial listed, which is actively recruiting participants.
MK-1406 is being studied in one clinical trial, NCT07743151, titled A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008). The trial is a Phase 1 study that is currently recruiting, with a planned enrollment of 400 participants in the United States.
The MK-1406 Phase 1 trial, NCT07743151, is a controlled, randomized study that is not double blinded. It enrolls 400 healthy volunteers age 18 and older, with all sexes eligible. The study is being conducted in the United States and is currently recruiting participants.
Yes. The Phase 1 trial of MK-1406, NCT07743151, is conducted in healthy participants rather than in patients with a specific disease. It is a controlled, randomized study enrolling 400 healthy volunteers age 18 and older in the United States.